Nautilus Biotechnology (NAUT) Capital Expenditures (2020 - 2026)
Nautilus Biotechnology (NAUT) reported Capital Expenditures of $510000.0 for Q1 2026, up 132.88% on a YoY basis from $219000.0 in Q1 2025, and up 109.02% sequentially from $244000.0 in Q4 2025.
Nautilus Biotechnology (NAUT) Capital Expenditures (2020 - 2026) Analysis & Trends
Nautilus Biotechnology (NAUT) has 7 years of Capital Expenditures data on file, last reported at $510000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 132.88% year-over-year to $510000.0; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (down 7.44% YoY), and the FY2025 full-year result was $1.3 million, down 39.82% from the prior year.
- Capital Expenditures advanced to $510000.0 in Q1 2026, from $244000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $963000.0 in Q3 2022 to a low of $219000.0 in Q1 2025.
- A 5-year average of $510294.1 and a median of $481000.0 in 2022 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 256.67% in 2022, while the deepest fall reached 76.77% in 2022.
- Tracing NAUT's Capital Expenditures over 5 years: stood at $229000.0 in 2022, then soared by 80.35% to $413000.0 in 2023, then plunged by 38.5% to $254000.0 in 2024, then dropped by 3.94% to $244000.0 in 2025, then jumped by 109.02% to $510000.0 in 2026.
- Business Quant data shows NAUT's Capital Expenditures at $510000.0 in Q1 2026, $244000.0 in Q4 2025, and $418000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Nautilus Biotechnology | 224.14 Mn | 224.14 Mn | - | 510,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 510,000.00 |
| Mar 31, 2026 | 510,000.00 |
| Dec 31, 2025 | 244,000.00 |
| Dec 31, 2025 | 244,000.00 |
| Sep 30, 2025 | 418,000.00 |
| Sep 30, 2025 | 418,000.00 |
| Jun 30, 2025 | 396,000.00 |
| Jun 30, 2025 | 396,000.00 |
| Mar 31, 2025 | 219,000.00 |
| Mar 31, 2025 | 219,000.00 |
| Dec 31, 2024 | 254,000.00 |
| Dec 31, 2024 | 254,000.00 |
| Sep 30, 2024 | 709,000.00 |
| Sep 30, 2024 | 709,000.00 |
| Jun 30, 2024 | 512,000.00 |
| Jun 30, 2024 | 512,000.00 |
| Mar 31, 2024 | 647,000.00 |
| Mar 31, 2024 | 647,000.00 |
| Dec 31, 2023 | 413,000.00 |
| Dec 31, 2023 | 413,000.00 |